Physicians’ Hierarchy of Tumor Biomarkers for Optimizing Chemotherapy in Breast Cancer Care
The Oncologist · 2024
DOI: 10.1093/oncolo/oyad198 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Halle H Thannickal und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Physicians, Oncologists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINR NIH HHS, NCI NIH HHS, AHRQ HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Tumor biomarkers are regularly used to guide breast cancer treatment and clinical trial enrollment. However, there remains a lack of knowledge regarding physicians’ perspectives towards biomarkers and their role in treatment optimization, where treatment intensity is reduced to minimize toxicity.
Methods
Thirty-nine academic and community oncologists participated in semi-structured qualitative interviews, providing perspectives on optimization approaches to chemotherapy treatment. Interviews were audio-recorded, transcribed, and analyzed by 2 independent coders utilizing a constant comparative method in NVivo. Major themes and exemplary quotes were extracted. A framework outlining physicians’ conception of biomarkers, and their comfortability with their use in treatment optimization, was developed.
Results
In the hierarchal model of biomarkers, level 1 is comprised of standard-of-care (SoC) biomarkers, defined by a strong level of evidence, alignment with national guidelines, and widespread utilization. Level 2 includes SoC biomarkers used in alternative contexts, in which physicians expressed confidence, yet less certainty, due to a lack of data in certain subgroups. Level 3, or experimental, biomarkers created the most diverse concerns related to quality and quantity of evidence, with several additional modulators.
Conclusion
This study demonstrates that physicians conceptualize the use of biomarkers for treatment optimization in successive levels. This hierarchy can be used to guide trialists in the development of novel biomarkers and design of future trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.
- University of Alabama at Birmingham, Department of Medicine, Division of Hematology and Oncology; Birmingham, AL, USA.
- University of Michigan, Departments of Internal Medicine and Epidemiology, Rogel Cancer Center, Ann Arbor, MI, USA.
- Wake Forest School of Medicine, Winston Salem, NC, USA.
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
- University of Alabama at Birmingham, Department of Medicine, Division of Gerontology, Geriatrics, and Palliative Care Birmingham, AL, USA.
ORCID-Profile: Halle H Thannickal
Förderung
- NINR NIH HHS
- NCI NIH HHS
- AHRQ HHS
- Johns Hopkins University
- National Institute of Nursing Research
Zitieren
APA
Thannickal, H. H., Eltoum, N., Henderson, N. L., Wallner, L. P., Wagner, L. I., Wolff, A. C., & Rocque, G. B. (2024). Physicians’ Hierarchy of Tumor Biomarkers for Optimizing Chemotherapy in Breast Cancer Care. The Oncologist. https://doi.org/10.1093/oncolo/oyad198
Vancouver
Thannickal HH, Eltoum N, Henderson NL, Wallner LP, Wagner LI, Wolff AC, et al. Physicians’ Hierarchy of Tumor Biomarkers for Optimizing Chemotherapy in Breast Cancer Care. The Oncologist. 2024. doi:10.1093/oncolo/oyad198
BibTeX
@article{Thannickal2024,
author = {Thannickal, Halle H and Eltoum, Noon and Henderson, Nicole L and Wallner, Lauren P and Wagner, Lynne I and Wolff, Antonio C and Rocque, Gabrielle B},
title = {Physicians’ Hierarchy of Tumor Biomarkers for Optimizing Chemotherapy in Breast Cancer Care},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyad198}
}
EUVIMED